Skip to main content

Mild Traumatic Brain Injury, Concussion

1
Pipeline Programs
3
Companies
3
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Oragenics
OragenicsLAKEWOOD RANCH, FL
1 program
1
Neurosteroid enantiomerPhase 21 trial
Active Trials
NCT06870240Not Yet Recruiting40Est. Mar 2026
Vivonics
VivonicsMA - Bedford
1 program
Stochastic Galvanic Vestibular StimulationN/A1 trial
Active Trials
NCT07466589Recruiting32Est. Mar 2026
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Vestibular therapy for mTBI augmented with audio and visual real-time biofeedbackN/A1 trial
Active Trials
NCT06381674Recruiting100Est. Sep 2028

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
OragenicsNeurosteroid enantiomer
VivonicsStochastic Galvanic Vestibular Stimulation
Oregon TherapeuticsVestibular therapy for mTBI augmented with audio and visual real-time biofeedback

Clinical Trials (3)

Total enrollment: 172 patients across 3 trials

NCT06870240OragenicsNeurosteroid enantiomer

A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury

Start: Jun 2025Est. completion: Mar 202640 patients
Phase 2Not Yet Recruiting
NCT07466589VivonicsStochastic Galvanic Vestibular Stimulation

Advancement of Vestibular Intervention Via Portable Electrical Stimulator (VIPES)

Start: Aug 2025Est. completion: Mar 202632 patients
N/ARecruiting
NCT06381674Oregon TherapeuticsVestibular therapy for mTBI augmented with audio and visual real-time biofeedback

Wearable Technology to Characterize and Treat mTBI Subtypes: Biofeedback-Based Precision Rehabilitation

Start: Jun 2024Est. completion: Sep 2028100 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 172 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.